L'etude clinique du mois. Apres la tempete sur les anorexigenes centraux, l'etude "STORM" avec la sibutramine.

Scheen, André

No full text

Article (Scientific journals)

L'etude clinique du mois. Apres la tempete sur les anorexigenes centraux, l'etude "STORM" avec la sibutramine.

Scheen, André

2001 • In Revue Médicale de Liège, 56 (1), p. 56-8

Peer reviewed

Permalink
https://hdl.handle.net/2268/12239

PubMed
11256141

Files (0)Send to Details Statistics Bibliography Similar publications

Files

Full Text

No document available.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Appetite Depressants/therapeutic use; Cardiovascular Diseases/etiology; Cyclobutanes/therapeutic use; Double-Blind Method; Europe; Humans; Multicenter Studies as Topic; Obesity/complications/drug therapy; Risk Factors; Treatment Outcome; Weight Loss

Abstract :

[en] The results of the "Sibutramine Trial of Obesity Reduction and Maintenance" (STORM) published in the last issue of December 2000 of the Lancet are summarized. This clinical trial (open label for the first 6 months and double blind versus placebo for a further 18 months) demonstrates the positive effect of sibutramine, a new anorectic drug, on long-term weight maintenance after weight loss in obese subjects. The benefit of sibutramine on the cardiovascular risk profile of the obese patient is more particularly discussed.

Disciplines :

Pharmacy, pharmacology & toxicology

Author, co-author :

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale

Language :

French

Title :

L'etude clinique du mois. Apres la tempete sur les anorexigenes centraux, l'etude "STORM" avec la sibutramine.

Alternative titles :

[fr] Clinical study of the month. After the storm over central anorectic agents, the "STORM" study of sibutramine

Publication date :

2001

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Hopital de Baviere, Liège, Belgium

Volume :

Issue :

Pages :

56-8

Peer reviewed :

Peer reviewed

Available on ORBi :

since 06 May 2009

Statistics

Number of views

35 (0 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Luyckx F., Scheen A.J., Lefèbvre P.J. (1999) L'obésité féminine: Souci esthétique ou problème médical?. Rev Med Liège 54:262-267.
Scheen A.J. (1999) L'"épidémie" des maladies métaboliques, un problème majeur de santé publique. Rev Med Liège 54:87-94.
Scheen A.J., Desaive C., Lefèbvre P.J. Therapy for obesity - Today and tomorrow. Baillière's Clin Endocrinol Metab 1994, 8:705-727.
Scheen A.J., Lefèbvre P.J. (1999) Pharmacological treatment of obesity : Present status. Int J Obesity 23(SUPPL. 1):47-53.
Carek P.J., Dickserson L.M. (1999) Current concepts in the pharmacological management of obesity. Drugs 57:883-904.
Scheen A.J. (1997) Haro sur les anorexigènes centraux!. Rev Med Liège 52:613-615.
Luyckx F.H., Scheen A.J. (2000) Recommandations pour le traitement de l'obésité. Rev Med Liège 55:367-371.
McNeely W., Goa K.L. (1998) Sibutramine. A review of its contribution in the management of obesity. Drugs 56:1093-1124.
Scheen A.J. (1999) Etudes cliniques à long terme (1-2 ans) avec l'orlistat, nouveau médicament pour le traitement de l'obésité. Rev Med Liège 54:707-709.
James W.P.T., Astrup A., Finer N. (2000) Effect of sibutramine on weight maintenance after weight loss: A randomised trial. Lancet 356:2119-2125.
Scheen A.J. (2000) Evidence-based medicine. Rev Med Liège 55:216-219.
(1995) Guidelines for the approval and use of drugs to treat obesity. Obes Res 3:473-478.
Luyckx F.H., Scheen A.J., Gielen J., Lefèbvre P.J. (1997) Comment j'explore ... le syndrome d'insulinorésistance grâce à ses marqueurs biologiques. Rev Med Liège 52:686-691.
Scheen A.J. (1999) Intérêt d'augmenter un taux de cholestérol HDL bas en prévention secondaire de la coronaropathie: Résultats de l'étude VA-HIT. Rev Med Liège 54:773-775.